Skip to main content

CXCL13/BLC/BCA-1 Antibody (MM0212-12A2) - Azide and BSA Free

Novus Biologicals, part of Bio-Techne | Catalog # NBP2-12222

Novus Biologicals, part of Bio-Techne

Key Product Details

Species Reactivity

Human

Applications

Block/Neutralize, Flow Cytometry, Immunohistochemistry, Western Blot

Label

Unconjugated

Antibody Source

Monoclonal Mouse IgG1 Clone # MM0212-12A2

Format

Azide and BSA Free

Concentration

LYOPH mg/ml

Product Specifications

Immunogen

Human recombinant CXCL13/BLC/BCA-1

Clonality

Monoclonal

Host

Mouse

Isotype

IgG1

Applications for CXCL13/BLC/BCA-1 Antibody (MM0212-12A2) - Azide and BSA Free

Application
Recommended Usage

Immunohistochemistry

1:50-1:100

Western Blot

1:500-1:1000

Formulation, Preparation, and Storage

Purification

Protein G purified

Reconstitution

Reconstitute with sterilized PBS to a final concentration of 0.5 mg/ml.

Formulation

Lyophilized from a 0.2 um filtered solution in PBS. 0.025 mg size is provided in liquid form, PBS

Format

Azide and BSA Free

Preservative

No Preservative

Concentration

LYOPH mg/ml

Shipping

The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.

Stability & Storage

Store at 4C short term. Aliquot and store at -20C long term. Avoid freeze-thaw cycles.

Background: CXCL13/BLC/BCA-1

Plasmid: pCMV-CXCL13 Full length; Host Cell: 293T

Alternate Names

ANGIE2, BCA-1, BCA1, BLC, BLR1L, SCYB13

Gene Symbol

CXCL13

UniProt

Additional CXCL13/BLC/BCA-1 Products

Product Documents for CXCL13/BLC/BCA-1 Antibody (MM0212-12A2) - Azide and BSA Free

Certificate of Analysis

To download a Certificate of Analysis, please enter a lot number in the search box below.

Product Specific Notices for CXCL13/BLC/BCA-1 Antibody (MM0212-12A2) - Azide and BSA Free

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Loading...
Loading...
Loading...
Loading...
Loading...
Loading...